Their prevalence is different according to the cancer type since it was found that IDH1 has higher incidence rate than IDH2 in brain cancers [91,92], while in AML they are equally common [93], likely reflecting the differential tumour metabolic needs. This evidence concerns the gene IDH1 and acute myeloid leukemia.